4-(2-甲基磺酰基苯基)苯胺 | 31433-65-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(2-甲基磺酰基苯基)苯胺
• 英文名称: 4-Amino-2'-methylsulfonyl-[1,1']biphenyl
• 英文别名: 2'-Methylsulfonyl-4-aminobiphenyl；2'-methylsulfonylbiphenyl-4-ylamine；2'-methanesulfonylbiphenyl-4-ylamine；4-(2-methylsulfonylphenyl)aniline
• CAS: 31433-65-5
• 化学式: C₁₃H₁₃NO₂S
• 分子量: 247.318
• InChiKey: DDXKAGIILGJQOZ-UHFFFAOYSA-N

物化性质

• 沸点：
  479.0±37.0 °C(Predicted)
• 密度：
  1.244±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  68.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(2-甲基磺酰基苯基)苯胺 在 盐酸 、 ammonium acetate 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 氯仿 为溶剂， 反应 24.0h， 生成 5-isoxazoleacetic acid, 3-<3-(aminoiminomethyl)phenyl>-5-<<<2'-(methylsulfonyl)<1,1'-biphenyl>-4-yl>amino>carbonyl>-4,5-dihydro-, methyl ester
  参考文献：
  名称：

  Design and Synthesis of Isoxazoline Derivatives as Factor Xa Inhibitors. 1

  摘要：

  Thrombosis is a major cause of mortality in the industrialized world. Therefore, the prevention of blood coagulation has become a major target for new therapeutic agents. One attractive approach is the inhibition of factor Xa (FXa), the enzyme directly responsible for protbrombin activation. We report a series of novel biaryl-substituted isoxazoline derivatives in which the biaryl moiety was designed to interact with the S-4 aryl-binding domain of the FXa active site. Several of the compounds herein have low nanomolar affinity for FXa, have good in vitro selectivity for FXa, and show potent antithrombotic efficacy in vivo, The three most potent compounds (33, 35, and 37) have inhibition constants for human FXa of 3.9, 2.3, and 0.83 nM, respectively, and ID50's ranging from 0.15 to 0.26 mu mol/kg/h in the rabbit arterio-venous thrombosis model.

  DOI：

  10.1021/jm980405i
• 作为产物：
  描述：

  2-methanesulfonyl-4'-nitrobiphenyl 在 氢气 作用下， 以 四氢呋喃 为溶剂， 反应 18.0h， 生成 4-(2-甲基磺酰基苯基)苯胺
  参考文献：
  名称：

  Substituted biphenyl derivatives

  摘要：

  本发明涉及公式I中的化合物，其中R1、R2、R3、R4和X具有文本中指示的含义。这些化合物可作为因子Xa和VIIa的抑制剂，因此可用于控制和预防血栓栓塞症状，如血栓形成、心肌梗死、动脉硬化、炎症、中风、心绞痛、血管成形术后再狭窄和间歇性跛行等。

  公开号：

  US06946489B2

文献信息

• Indazole-derivatives as factor Xa inhibitors
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1479675A1

  公开（公告）日：2004-11-24

  The present invention relates to compounds of the formulae I and Ib wherein R0 ; R1 ; R2 ;Q; V, G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formulae I and Ib, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及式I和Ib的化合物 其中R0; R1; R2; Q; V，G和M具有索赔中指示的含义。式I的化合物是有价值的药理活性化合物。它们表现出强烈的抗血栓作用，例如，适用于治疗和预防心血管疾病，如血栓栓塞疾病或再狭窄。它们是血液凝块酶因子Xa（FXa）和/或因子VIIa（FVIIa）的可逆抑制剂，通常可应用于因子Xa和/或因子VIIa的不良活性存在或因子Xa和/或因子VIIa的抑制而打算治愈或预防的情况。此外，本发明还涉及制备式I和Ib的化合物的方法，它们的用途，特别是作为药物中的活性成分，并包括它们的制药制剂。
• Phenyl-isoxazoles as factor XA Inhibitors
  申请人：Dupont Pharmaceuticals Company

  公开号：US06187797B1

  公开（公告）日：2001-02-13

  The present application describes oxygen and sulfur containing heteroaromatics and derivatives thereof of formula or pharmaceutically acceptable salt or prodrug forms thereof, wherein J is O or S and D may be C(═NH)NH2, which are useful as inhibitors of factor Xa.

  本申请描述了氧和硫含杂芳烃及其衍生物的化学式，其中J为O或S，D可能为C(═NH)NH2，或其药用盐或前药形式，这些化合物可作为因子Xa的抑制剂。
• Biphenyl series—I
  作者：C. Dell'Erba、G. Garbarino、G. Guanti

  DOI：10.1016/s0040-4020(01)92402-0

  日期：——

  The synthesis of a range of 2′-, 3′- and 4′-substituted 3-nitro-4-bromobiphenyls and of their intermediates is described.

  描述了一系列2'-，3'-和4'-取代的3-硝基-4-溴代二苯及其中间体的合成。
• Cyclic amino acid derivatives
  申请人：——

  公开号：US20030176465A1

  公开（公告）日：2003-09-18

  Novel compounds of the formula I 1 in which R 1 , R 2 , R 2′ , R 2″ , R 3 , R 4 , R 5 , R 5′ , R 5″ , R 5′″ , R 5″″ , X, Y, U, V and W are as defined in Patent claim 1, are inhibitors of coagulation factors Xa and VIIa and can be employed fr the treatment of thromboses, myocardilal infarction, arteriosclerosis, inflammation, apoplexia, angina pectoris, restenosis after angioplasty, claudicatio intermittens, tumours, tumour diseases and/or tumour metastases.

  化合物I1的新颖化合物，其中R1、R2、R2'、R2"、R3、R4、R5、R5'、R5"、R5'"、R5""、X、Y、U、V和W的定义如专利权利要求书中所述，是凝血因子Xa和VIIa的抑制剂，可用于治疗血栓、心肌梗塞、动脉硬化、炎症、中风、心绞痛、血管成形术后再狭窄、间歇性跛行、肿瘤、肿瘤疾病和/或肿瘤转移。
• [EN] INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE<br/>[FR] INHIBITEURS DE FACTEUR XA ET AUTRES SERINE PROTEASES INTERVENANT DANS LA CASCADE DE COAGULATION
  申请人：WARNER LAMBERT CO

  公开号：WO2004024679A1

  公开（公告）日：2004-03-25

  This invention discloses amino acid derivatives which display inhibitory effects on the serine protease factor Xa. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, methods for the preparation of the compounds, and methods of using them as therapeutic agents for treating or preventing disease states in mammals characterized by abnormal thrombosis.

  该发明揭示了显示对丝氨酸蛋白酶Xa具有抑制作用的氨基酸衍生物。该发明还揭示了该化合物的药用盐、包含该化合物或其盐的药用组合物、制备该化合物的方法，以及将其用作治疗或预防哺乳动物异常血栓形成疾病状态的治疗剂的方法。